Journal
NEUROPHARMACOLOGY
Volume 223, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2022.109329
Keywords
AdenosineA1 receptor; AdenosineA2A receptor; G protein-coupled receptor heteromers; Glutamate release; Acetylcholine release; Dopamine release; Striatum; Parkinson?s disease; Restless legs syndrome
Categories
Ask authors/readers for more resources
Adenosine plays a significant role in modulating striatal neurotransmission, which is mediated by A1 and A2A receptors. The modulation involves different components of the striatal microcircuit and the formation of heteromers. These heteromers have unique properties and provide fine-tune modulation of striatal glutamate release. Targeting these adenosine receptor heteromers may be important for drug development in neuropsychiatric disorders.
Adenosine plays a very significant role in modulating striatal glutamatergic and dopaminergic neurotransmis-sion. In the present essay we first review the extensive evidence that indicates this modulation is mediated by adenosine A1 and A2A receptors (A1Rs and A2ARs) differentially expressed by the components of the striatal microcircuit that include cortico-striatal glutamatergic and mesencephalic dopaminergic terminals, and the cholinergic interneuron. This microcircuit mediates the ability of striatal glutamate release to locally promote dopamine release through the intermediate activation of cholinergic interneurons. A1Rs and A2ARs are colo-calized in the cortico-striatal glutamatergic terminals, where they form A1R-A2AR and A2AR-cannabinoid CB1 receptor (CB1R) heteromers. We then evaluate recent findings on the unique properties of A1R-A2AR and A2AR- CB1R heteromers, which depend on their different quaternary tetrameric structure. These properties involve different allosteric mechanisms in the two receptor heteromers that provide fine-tune modulation of adenosine and endocannabinoid-mediated striatal glutamate release. Finally, we evaluate the evidence supporting the use of different heteromers containing striatal adenosine receptors as targets for drug development for neuropsy-chiatric disorders, such as Parkinson's disease and restless legs syndrome, based on the ability or inability of the A2AR to demonstrate constitutive activity in the different heteromers, and the ability of some A2AR ligands to act preferentially as neutral antagonists or inverse agonists, or to have preferential affinity for a specific A2AR heteromer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available